相关实验视频

Updated: Jun 8, 2026

Serum and Plasma Copy Number Detection Using Real-time PCR

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

在转移性化敏感前列腺癌中使用阿帕胺:来自多中心真实世界ARON-3研究的结果

Matteo Santoni¹, Thomas Büttner², Pasquale Rescigno³

¹Medical Oncology Unit, Macerata Hospital, Macerata, Italy.

European urology oncology

|November 29, 2024

概括

阿帕胺在现实环境中有效治疗转移性割敏感前列腺癌. 该研究发现前列腺特异性抗原反应的高率和良好的耐受性,支持其使用.

科学领域:

在瘤学瘤学.
泌尿器科泌尿器科泌尿器科泌尿器科
药理学药理学是指药理学的学科.

背景情况:

转移性割敏感前列腺癌 (mCSPC) 需要有效的治疗选择.
阿帕胺 (APA) 是一种用于mCSPC的雄激素受体抑制剂.

研究的目的:

评估阿帕胺在mCSPC患者中的实际有效性和耐受性.
评估临床结果,包括整体生存率和前列腺特异性抗原 (PSA) 反应率.

主要方法:

在ARON-3研究中,对531名mCSPC患者接受 apalutamide 治疗的回顾性分析.
评估的结果包括整体存活率 (OS),PSA90 (≥90%的PSA下降) 和PSA0.2 (PSA ≤0.2 ng/ml).
使用常用术语标准对不良事件v5.0.0收集和分类不良事件.

主要成果:

没有达到中位数的OS. 观察到PSA90 (87%) 和PSA0.2 (69%) 的高率.
显著更长的中位 OS 与实现 PSA90 或 PSA0.2 (p < 0.001) 相关.
3-4级疲劳在老年患者 (≥80岁) 中更常见,但其他不良事件在不同年龄组中是可比的.

结论:

阿帕胺在实现PSA反应方面表现出有效性,并且在现实世界mCSPC群体中耐受良好.
来自ARON-3研究的现实数据支持阿帕胺的疗效和安全性,与临床试验结果一致.

关键词:

在ARON-3的试验中,ARON-3的试验.雄激素受体通路抑制剂亚帕胺胺是什么意思对割敏感的前列腺癌荷尔蒙敏感的敏感的荷尔蒙前列腺癌是什么意思前列腺癌是什么意思

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...